The safety and efficacy of this drug in T2DM patients were evaluated in the DUAL program, in DUAL V study it was compared with basal insulin alone, finding a significant decrease in HbA1c and additionally weight loss and lower risk of hypoglycemia (8). This evidence concerns the gene INS and type 2 diabetes mellitus.